Results 231 to 240 of about 327,411 (314)
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink +9 more
wiley +1 more source
The Intriguingly Social N400 of Preverbal Infants. [PDF]
Forgács B +6 more
europepmc +1 more source
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest +4 more
wiley +1 more source
After the green light: Evaluating drugs in Phase IV studies.
Meher BR, Mishra A.
europepmc +1 more source
Ceftriaxone‐induced liver injury: Incidence, phenotypic characterization and predictive factors
Introduction Ceftriaxone is a widely used third‐generation cephalosporin in hospitalized patients. Although generally considered safe, it has been associated with hepatobiliary complications and emerging reports of drug‐induced liver injury (DILI). However, data on its true incidence, phenotypic patterns, and predictors remain limited. This study aimed
Mohamed Hatem +5 more
wiley +1 more source
Pragmatic trial assessing polygenic risk driven statin therapy for cardiovascular disease prevention: study protocol for the EE-PRS trial. [PDF]
Voit A +13 more
europepmc +1 more source
Prior glucocorticoid exposure is associated with modestly increased vancomycin clearance in hospitalized children, partly mediated by renal function and inflammation and may contribute to subtherapeutic early drug exposure. Abstract Introduction Augmented renal clearance (ARC) can lead to subtherapeutic vancomycin exposure in children.
Kouki Tomari +6 more
wiley +1 more source
Response to the letter: "Comment on A cost-utility analysis of pharmacopuncture versus physiotherapy for chronic low back pain: A multicenter, pragmatic randomized controlled trial". [PDF]
Lee YS, Han CH, Ha IH.
europepmc +1 more source

